A two-day Diabetic and
Endocrime Summit, beginning here tomorrow, would discuss, among others, The Novel Drug Delivery Systems,involving SGLT-2 (Sodium Glucose Co Transporter) Inhibitors.
This new drug has wondeful advantage of reducing weight along with blood sugar control, which will be available in the next few days in Indian market, Dr Suresh Damodaran, Head of Department of Diabetes and Endocrinology, Sri Ramakrishna Hospital, told reporters here.
It has to be seen how these tablets, manufactured by foreign pharmas, would be beneficial to India, where 62 million are diagnosed with diabetes, Suresh said.
More than 500 delegates from all over Tamil Nadu and a few senior endocrinologists will participate.
